Shinji Yamazaki

6.0k total citations · 3 hit papers
76 papers, 3.0k citations indexed

About

Shinji Yamazaki is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shinji Yamazaki has authored 76 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 23 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shinji Yamazaki's work include Lung Cancer Treatments and Mutations (14 papers), Pharmacogenetics and Drug Metabolism (12 papers) and Drug Transport and Resistance Mechanisms (12 papers). Shinji Yamazaki is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Pharmacogenetics and Drug Metabolism (12 papers) and Drug Transport and Resistance Mechanisms (12 papers). Shinji Yamazaki collaborates with scholars based in United States, Japan and Belgium. Shinji Yamazaki's co-authors include Helen Y. Zou, James G. Christensen, Joseph H. Lee, Qiuhua Li, Gerrit Los, Maria E. Arango, Barbara Mroczkowski, Gordon Alton, Scott R. McDonnell and Tatiana Koudriakova and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Clinical Cancer Research.

In The Last Decade

Shinji Yamazaki

71 papers receiving 2.9k citations

Hit Papers

An Orally Available Small-Molecule Inhibitor of c-Met, PF... 2007 2026 2013 2019 2007 2008 2007 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
    2007 593 citations Helen Y. Zou, Qiuhua Li et al. Cancer Research profile →
  2. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
    2008 515 citations Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research profile →
  3. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
    2007 513 citations James G. Christensen, Helen Y. Zou et al. Molecular Cancer Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shinji Yamazaki United States 25 1.4k 1.2k 1.1k 326 320 76 3.0k
Cody J. Peer United States 33 1.8k 1.2× 1.5k 1.3× 559 0.5× 351 1.1× 450 1.4× 156 4.0k
Jan H. Beumer United States 40 2.3k 1.7× 2.1k 1.8× 683 0.6× 489 1.5× 286 0.9× 234 4.8k
E. Brendel Germany 21 891 0.6× 818 0.7× 558 0.5× 310 1.0× 269 0.8× 53 2.1k
Raymond J. Hohl United States 40 2.3k 1.6× 1.5k 1.3× 624 0.6× 818 2.5× 366 1.1× 138 4.9k
Paul Statkevich United States 35 1.6k 1.1× 2.1k 1.7× 971 0.9× 646 2.0× 186 0.6× 92 4.8k
Tristan M. Sissung United States 30 1.2k 0.9× 1.4k 1.2× 635 0.6× 506 1.6× 143 0.4× 94 2.9k
Tomoko Oh‐hara Japan 31 2.0k 1.4× 1.7k 1.5× 400 0.4× 364 1.1× 233 0.7× 65 3.4k
Juan José Pérez Ruixo United States 28 1.0k 0.7× 1.6k 1.3× 505 0.5× 415 1.3× 164 0.5× 148 3.4k
John P. Fruehauf United States 37 2.1k 1.5× 1.4k 1.2× 567 0.5× 756 2.3× 231 0.7× 100 4.2k
George G. Chen Hong Kong 31 2.2k 1.6× 862 0.7× 421 0.4× 1.1k 3.4× 282 0.9× 119 3.6k

Countries citing papers authored by Shinji Yamazaki

Since Specialization
Citations

This map shows the geographic impact of Shinji Yamazaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinji Yamazaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinji Yamazaki more than expected).

Fields of papers citing papers by Shinji Yamazaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shinji Yamazaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinji Yamazaki. The network helps show where Shinji Yamazaki may publish in the future.

Co-authorship network of co-authors of Shinji Yamazaki

This figure shows the co-authorship network connecting the top 25 collaborators of Shinji Yamazaki. A scholar is included among the top collaborators of Shinji Yamazaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinji Yamazaki. Shinji Yamazaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Nakayama, Shinji, Kota Toshimoto, Shinji Yamazaki, Jan Snoeys, & Yuichi Sugiyama. (2023). Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B. CPT Pharmacometrics & Systems Pharmacology. 12(10). 1461–1472. 3 indexed citations
3.
Costales, Chester, Jian Lin, Emi Kimoto, et al.. (2021). Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling. CPT Pharmacometrics & Systems Pharmacology. 10(9). 1018–1031. 39 indexed citations
4.
Yamazaki, Shinji, et al.. (2018). EFFICIENCY AND SOPHISTICATION OF DESIGN AND CONSTRUCTION OF WAVE-DISSIPATING WORKS USING 3D DATA. Journal of Japan Society of Civil Engineers Ser B3 (Ocean Engineering). 74(2). I_1–I_6.
5.
Spilker, Mary E., Xiaoying Chen, Ravi Visswanathan, et al.. (2016). Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies. Clinical Cancer Research. 23(4). 1080–1090. 23 indexed citations
6.
Wojciechowicz, Donald, Wenyue Hu, Winston Evering, et al.. (2012). Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901. Molecular Cancer Therapeutics. 11(10). 2274–2283. 8 indexed citations
7.
Zou, Helen Y., Qiuhua Li, Joseph H. Lee, et al.. (2012). Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor. Molecular Cancer Therapeutics. 11(4). 1036–1047. 57 indexed citations
8.
Yamazaki, Shinji & Susumu Minami. (2010). ENERGY ABSORPTION CAPACITY OF STEEL BEAMS SUBJECTED TO CYCLIC BENDING MOMENT. Journal of Structural and Construction Engineering (Transactions of AIJ). 75(652). 1149–1157. 1 indexed citations
9.
Hu‐Lowe, Dana D., Helen Y. Zou, Maren L. Grazzini, et al.. (2008). Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clinical Cancer Research. 14(22). 7272–7283. 515 indexed citations breakdown →
10.
Yamazaki, Shinji, et al.. (2007). RESPONSE CONTROL EFFECT OF COUPLED VIBRATION CONTROL STRUCTURES USING HYSTERESIS DAMPER UNDER GROUND MOTION. Journal of Structural and Construction Engineering (Transactions of AIJ). 72(621). 49–56.
11.
Christensen, James G., Helen Y. Zou, Maria E. Arango, et al.. (2007). Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular Cancer Therapeutics. 6(12). 3314–3322. 513 indexed citations breakdown →
12.
Zou, Helen Y., Qiuhua Li, Joseph H. Lee, et al.. (2007). An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms. Cancer Research. 67(9). 4408–4417. 593 indexed citations breakdown →
13.
Marrone, Tami, Dana D. Hu‐Lowe, Maren L. Grazzini, et al.. (2007). PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2. Cancer Research. 67. 3992–3992. 7 indexed citations
14.
Yamazaki, Shinji, Maren L. Grazzini, David Romero, et al.. (2005). PK/PD modeling based on mouse xenograft tumor growth inhibition and the correlation to clinical exposure for VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736. Cancer Research. 65. 705–706. 2 indexed citations
15.
16.
Yamazaki, Shinji, et al.. (2000). STABILITY RATIO AND DYNAMIC P-ΔEFFECTS IN INELASTIC EARTHQUAKE RESPONSE. Journal of Structural and Construction Engineering (Transactions of AIJ). 65(527). 71–78. 2 indexed citations
17.
Yamazaki, Shinji & Susumu Minami. (1999). EXPERIMENTAL STUDY ON INELASTIC BEHAVIOR OF STEEL BEAM-COLUMNS SUBJECT TO VARYING AXIAL FORCE AND CYCLIC LATERAL LOAD. Journal of Structural and Construction Engineering (Transactions of AIJ). 64(519). 95–102. 1 indexed citations
18.
Yamazaki, Shinji, et al.. (1993). Wind Resistant Design and Response Control of Tall Building. 532–537. 4 indexed citations
19.
Yamazaki, Shinji. (1992). Structural Design of the Landmark Tower in Yokohama.. JOURNAL OF THE JAPAN WELDING SOCIETY. 61(2). 107–112. 2 indexed citations
20.
Yamazaki, Shinji, et al.. (1979). Theoretical Consideration on a Control of Jib-Crane. Transactions of the Society of Instrument and Control Engineers. 15(6). 826–832. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cody J. Peer Breakdown of academic impact, for papers by Jan H. Beumer Breakdown of academic impact, for papers by E. Brendel Breakdown of academic impact, for papers by Raymond J. Hohl Breakdown of academic impact, for papers by Paul Statkevich Breakdown of academic impact, for papers by Tristan M. Sissung Breakdown of academic impact, for papers by Tomoko Oh‐hara Breakdown of academic impact, for papers by Juan José Pérez Ruixo Breakdown of academic impact, for papers by John P. Fruehauf Breakdown of academic impact, for papers by George G. Chen
Rankless by CCL
2026